Granules India (GRANULES) | Stock Overview & Key Data
Granules India Performance Comparison
Stock Range
Today's Range
Low: ₹542.00
High: ₹562.70
on October 3, 2025
52 Week Range
Low: ₹422.00
High: ₹628.00
on April 9, 2025
on December 3, 2024
All-Time High: ₹721.00 on August 26, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR139.0B
EPS
19.75
P/E Ratio (TTM)
27.57
Forward P/E
19.34
P/B Ratio
3.55
PEG Ratio
-1.67
Div. Yield
0.30%
ROE
13.50%
Beta
-0.144
Debt to Equity
39.15
Financial Highlights
Profitability
Gross Margin
64.84%
Operating Margin
14.70%
Profit Margin
10.63%
Returns and Earnings
Return on Assets (TTM)
8.02%
Return on Equity (TTM)
13.50%
EBITDA
INR9.5B
Net Income (TTM)
INR4.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR186.02
Quarterly Revenue Growth (YoY)
2.60%
Quarterly Earnings Growth (YoY)
-16.30%
Dividend Information
Last 12-Month Dividend
₹1.50
Current Dividend Yield
0.30%
3-Year Average Dividend Yield
0.33%
3-Year Average Annual Dividend
₹1.50
3-Year Total Dividends
₹4.50
Ex-Dividend Date
July 31, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Granules India GRANULES | 139.00B Mid-cap | 8.02% | 7.49% | 13.70% | 13.46% | -6.71% | -2.19% | 60.05% | 47.36% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Neuland Laboratories NEULANDLAB | 198.78B Mid-cap | 8.80% | 5.76% | 30.23% | 26.07% | 6.30% | 25.94% | 926.28% | 1,106.52% |
| Alembic APLLTD | 182.09B Mid-cap | 0.05% | -4.74% | -9.63% | 2.62% | -13.21% | -26.75% | 47.43% | -5.00% |
| Jubilant Pharmova JUBLPHARMA | 171.19B Mid-cap | -0.50% | 3.66% | -10.84% | 17.71% | -0.05% | -2.93% | 210.44% | 101.03% |
Ownership & Short Interest
Insider Ownership
40.15%
Institutional Ownership
24.68%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GRANULES's 52-week high and low?
- In the last 52 weeks, Granules India reached a high of ₹628.00 (on December 3, 2024) and a low of ₹422.00 (on April 9, 2025).
- What is the market cap and P/E ratio for GRANULES?
- Curious about Granules India's size and valuation? Its market capitalization stands at 139.00B. When it comes to valuation, the P/E ratio (trailing twelve months) is 27.57, and the forward P/E (looking ahead) is 19.34.
- Does GRANULES pay dividends? If so, what's the yield?
- Yes, Granules India is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.30%, and the company has paid an average of ₹1.50 per share annually over the past 3 years.
- Who are Granules India's main competitors or similar companies to consider before investing?
When looking at Granules India, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Neuland Laboratories
NEULANDLAB198.78B Healthcare Drug Manufacturers - Specialty & Generic 25.94% 926.28% Alembic
APLLTD182.09B Healthcare Drug Manufacturers - Specialty & Generic -26.75% 47.43% Jubilant Pharmova
JUBLPHARMA171.19B Healthcare Drug Manufacturers - Specialty & Generic -2.93% 210.44% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Granules India Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Granules India's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.50%, the Debt to Equity ratio from the most recent quarter is 39.15, and its Gross Profit Margin stands at 64.84%.
- What is the recent revenue and earnings growth for GRANULES?
- Looking at Granules India's growth, its revenue over the trailing twelve months (TTM) was INR45B. Compared to the same quarter last year (YoY), quarterly revenue grew by 2.60%, and quarterly earnings saw a YoY growth of -16.30%.
- How much of GRANULES stock is held by insiders and institutions?
- Wondering who owns Granules India stock? Company insiders (like executives and directors) hold about 40.15% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 24.68%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.